Claudia Lin


Dr. Claudia Lin is the General Manager for AlphaMab Co. Ltd, a leading Chinese biotech company known for its strong R&D capabilities. She is overall responsible for the strategy, funding and implementation of the clinical development and commercialization of the company’s proprietary novel biologics in China and globally.

Prior to AlphaMab, Dr. Lin was Head of Quality for Innovent Biologics in China, where she built the international standard GMP capabilities from ground up in order to support the on-going clinical development programs.